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Abstract 
Over the last 10 years there have been considerable changes in how we manage 
Barrett’s, with the shift away from conventional surgery towards endotherapy 
for treating dysplasia and early cancer. In this editorial we will review these 
changes and look forward to the possible developments which may occur over 
the next decade. 
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The last ten years has witnessed significant changes in the examination and 
management of Barrett’s neoplasia. Where it was previously believed that 
dysplastic changes were invisible, the advances in endoscopic techniques and 
technology has made it possible to detect and localize early neoplasia in Barrett’s 
oesophagus. This has opened up a wealth of therapeutic options, such that there 
has been a complete shift away from the surgical treatment of high grade 
dysplasia and early mucosal cancer towards endoscopic therapy. Endotherapy is 
the recommended treatment of high grade dysplasia (HGD) by the ASGE [1]  and 
is the preferred treatment  over oesophagectomy in the recently updated BSG 
guidelines [2].  
 
There are now several endoscopic techniques for treating neoplasia within 
Barrett’s. These can broadly be divided into endoscopic resection, using either 
piecemeal EMR with a duette cap / cap and snare, or en-bloc resection using an 
endoscopic knife, and ablative techniques such as radiofrequency ablation (RFA), 
cryotherapy and argon plasma coagulation (APC). These techniques are 
complementary and it is increasingly becoming accepted that multi-modality 
therapy results in the best outcome. 
 
There is a growing body of data suggesting that EMR for HGD in Barrett’s results 
in an excellent outcome [3,4]. When used as single modality therapy it does 
however result in high recurrence rates of up to 36.7% [5]. This can be reduced 
to 3% if residual Barrett’s is ablated after all visible neoplasia is resected [6]. 
EMR is essential for all visible lesions and should be considered the ideal 
treatment for flat neoplasia made visible with advanced imaging techniques. It is 
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our contention that careful assessment with advanced imaging is essential. 
Usually when a lesion is visible on white light then the true extent of the lesion is 
best seen with advanced imaging technique and is generally bigger then what is 
obvious on white light. It is mandatory to mark the margins of the lesion using 
advanced imaging technique before endoscopic resection (ER). The band ligation 
and cap and snare techniques are both equally effective [7] and either could be 
used depending on the endoscopist’s experience. 
 
Ablative techniques can be used as monotherapy for completely flat and invisible 
neoplasia. However, attention should be paid to the UK RFA experience. This was 
not a study purely of RFA and did permit EMR. Early publication suggested a 
high rate of progression to cancer (3% at 12 months increasing to 5.1% at 19 
months) [8]. A subsequent follow up publication on the same series suggested 
that over time the amount of EMR performed pre RFA increased from 48% of 
cases to 60% of cases, with a fall in the need for rescue EMR from 13% to 2% [9]. 
It is reasonable to hypothesise that this was a result of better case selection with 
increased recognition of visible lesions over time and more ER prior to RFA. RFA 
does not result in a tissue specimen so it is important that all visible lesions are 
resected and sent for histology for proper staging prior to RFA.  
 
It is increasingly recognized that true low grade dysplasia (LGD) is associated 
with a significant risk of progression to cancer. RFA as a monotherapy can be 
effective in these cases, where visible nodules are uncommon and complete 
eradication of Barrett’s can be achieved. The situation in metaplastic Barrett’s 
however is quite different. Given the low risk of malignant progression in this 
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cohort it is our contention that it is unlikely to represent a cost-effective option 
at this stage. Furthermore, without long term follow up data it would be difficult 
to be certain that ongoing surveillance was unnecessary. Therefore patients 
would still need endoscopic surveillance negating many of the benefits of 
ablation in this group. 
 
Endoscopic therapy is also effective for intra-mucosal cancer (IMC). A large 
series of 1000 cases from Germany has demonstrated cure rates comparable 
with oesophagectomy with no patients dying from advanced cancer in the series 
[10]. Likewise, providing invasion does not extend beyond the upper third of the 
sub-mucosa (Sm1) the risk of lymph node metastasis is very low (6%) [11] and 
some centres are not considering these patients for surgery. The available 
literature is limited and Pathologists find it difficult to distinguish between 
superficial & deep  SM invasion especially on piecemeal resection specimen so 
careful consideration should be given to the management of these patients. 
  
 
There has been much controversy around the role of endoscopic submucosal 
dissection (ESD) in the treatment of Barrett’s neoplasia. ESD carries the 
advantage of yielding an enbloc specimen where invasion depth and lateral 
margins can be assessed more accurately. However, such techniques are 
technically challenging and are associated with higher complication rates, 
including perforation. Furthermore, with excellent results achievable using EMR 
/ RFA combination therapy it has been questioned whether the clinical gains are 
significant.  
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It is our contention however that ESD does have an important role in the 
treatment of Barrett’s neoplasia.  The literature suggests that nodular lesions in 
Barrett’s are highly likely to be cancerous rather then dysplastic. We believe that 
if the lesion is larger then 20 mm then it is not possible to resect it en-bloc using 
standard EMR technique and should be resected by ESD. A couple of studies 
[12,13] have proven the safety, efficacy and feasibility of ESD for Barrett’s 
neoplasia in western hands. ESD outcomes will purely depend on the skills and 
experience of the endoscopist. The ESD learning curve is long and steep in 
stomach and colon but we believe that ESD in the oesophagus is less challenging 
than in the colon and it is not impossible for western endoscopists to master this 
technique. In the coming decade, ESD technique is likely to evolve and become 
easier, faster and safer. As the endoscopist’s expertise and skills continue to rise, 
we are likely to see lot more ESD in the coming decade. It is very important to 
note that an inexperienced endoscopist performing ESD in the oesophagus can 
do a lot of harm so we call for strict training standards and careful monitoring of 
outcome if ESD is used in the oesophagus. 
It is only by having endoscopists who are able to offer the full range of 
endosocopic therapies (EMR, ESD and ablative techniques) that we will move to 
making decisions based on pathology rather than availability of skills. This will 
be the biggest challenge to be faced over the next decade 
 
Summary 
Endoscopic therapy has replaced conventional surgery as the gold standard of 
care for patients with dysplasia or early mucosal cancer within Barrett’s. It has 
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become clear that endoscopic resection of all visible neoplasia followed by 
ablation of residual metaplastic Barrett’s results in the best long term outcome. 
Ablation can be used as a monotherapy for patients with LGD or completely flat 
HGD, although the number of cases of the latter will be low and endoscopic 
resection of all visible neoplasia should be considered as the best approach to 
treatment. 
 
Whilst the last decade has seen the transition from surgical to endoscopic 
treatment of Barrett’s neoplasia, we believe that the next decade will see the 
refinement of these endoscopic techniques. ESD will become more common for 
selected lesions like early Sm invasive cancer where surgery is contraindicated. 
This will require development of good training facilities and refinement of the 
technique to make it easier and safer. Choices for ablation techniques will 
increase and the current techniques will evolve to become quicker and more 
effective. 
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